2,2,5,7,8-pentamethyl-1-hydroxychroman has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eickhoff, JC; Heath, EI; Kolesar, J; Kyriakopoulos, CE; Liu, G; Moll, T; Wilding, G; Yayehyirad, M | 1 |
| Thompson, TA; Wilding, G | 1 |
1 trial(s) available for 2,2,5,7,8-pentamethyl-1-hydroxychroman and Cancer of Prostate
| Article | Year |
|---|---|
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Chromans; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Vitamin E | 2016 |
1 other study(ies) available for 2,2,5,7,8-pentamethyl-1-hydroxychroman and Cancer of Prostate
| Article | Year |
|---|---|
Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.
Topics: Androgen Antagonists; Antioxidants; Chromans; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured; Vitamin E | 2003 |